Comparing efficacies of different treatment regimens in patients with hepatocellular carcinoma accompanied by portal vein tumor thrombus using network meta-analysis

Seungji Lee*, Sung Kyu Song*, Byungje Bae, Yongkeun Park
Department of Surgery, Catholic Kwandong University International St. Mary’s Hospital, Incheon, Korea

INTRODUCTION

Primary liver cancer accounts for 8.3% of cancer deaths. It is the 4th leading cause of cancer-related death in the world [1]. Hepatocellular carcinoma (HCC) accounts for a major proportion of primary liver cancer. Its incidence is on the rise in the Americas and most European countries. It is still the highest in East Asia. Common causes of HCC are HBV, HCV, alcohol, and nonalcoholic steatohepatitis [2]. Although many efforts have been made to manage HCC, its prognosis is still poor. The

Purpose: Although various treatment regimens have been introduced for hepatocellular carcinoma (HCC) accompanied by portal vein tumor thrombosis (PVTT), comprehensive and direct comparisons between them are limited. Thus, the purpose of this study was to perform a network meta-analysis (NMA) to compare the efficacies of different treatment regimens for HCC accompanied by PVTT.

Methods: A systematic review was conducted to identify studies comparing 2 or more treatment regimens for HCC accompanied by PVTT without extrahepatic metastasis and reporting each overall survival (OS). Endpoints of this NMA were to hazard ratios with confidential intervals for OS and mean survival time difference of each treatment regimen comparison using a random-effects model. Each treatment regimen was then ranked using the P-score to assess the probability of the superiority of each one.

Results: Eleven studies involving 1,623 patients that yielded 16 comparisons were identified and enrolled in this NMA. There were 12 different treatment regimens as comparators, including sorafenib therapy alone [reference treatment]. The NMA suggested that the following 4 treatment regimens improved OS compared to sorafenib: surgical resection followed by portal vein chemotherapy (SR plus PVC), SR, radiofrequency ablation plus sorafenib, and transarterial chemoembolization combined with selective internal radiation therapy. SR plus PVC was ranked the best treatment regimen for OS (P-score, 93.9%).

Conclusion: Comparative efficacy based on this NMA may help clinicians select treatment for HCC accompanied by PVTT. If amenable, aggressive locoregional treatment regimens such as SR plus PVC should be considered for HCC accompanied by PVTT.

Key Words: Carcinoma, Hepatectomy, Hepatocellular, Portal vein, Radiotherpay, Sorafenib
survival rate of HCC decreases dramatically year by year. One of the contributing factors to such a poor prognosis is the presence of tumor thrombus in portal vein or hepatic vein at the time of diagnosis [3,4]. Cancer cells can disseminate through bloodstream where vascular invasion is present, leading to a high recurrence rate [5]. Tumor thrombus can also deteriorate remnant liver function by reducing blood supply [6].

In Barcelona Clinic Liver Cancer (BCLC) staging, HCC accompanied by portal vein tumor thrombus (PVTT) is classified as advanced stage. Other associations such as the European Association for the Study of the Liver and the American Association of the Study of Liver Diseases follow the BCLC staging classification. Without treatment, expected median survival time of patients with HCC accompanied by PVTT is only 2.7–4.0 months [5]. PVTT is a relatively stronger factor affecting mortality than extrahepatic spread or performance status [6].

Considering expected survival time, the BCLC staging system does not recommend curative treatments to patients with HCC accompanied by PVTT. Instead, systemic therapy such as sorafenib is recommended currently. However, the outcome of sorafenib therapy remains unsatisfactory, with overall survival (OS) time of only 6–8 months [2]. Under these circumstances, various therapeutic approaches have been made for improving OS, such as treatment with surgical resection (SR), radioembolization, transcatheter arterial chemoembolization (TACE), and combination of these treatments [5]. Recently, studies have reported that these treatments can give better survival outcomes than sorafenib [5,7]. Nonetheless, it is still unclear which of these treatments yields better outcomes. In addition, most previous studies compared survival outcomes with a retrospective observational method.

Designing a prospective randomized controlled study that directly compares the priority of each treatment modality in patients with HCC accompanied by PVTT has practical limitation. While traditional meta-analysis can perform direct treatment comparison, it is not suitable for comparison between multiple treatment groups. Network meta-analysis can help decision-making by comparing multiple competing treatments in a single analysis even when there is no direct comparison between 2 specific treatments. Thus, the aim of this study was to determine the relative effectiveness and priorities of different treatment regimens for patients with HCC accompanied by PVTT using network meta-analysis.

**METHODS**

This meta-analysis study followed the guidelines of PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses). It was registered with the PROSPERO database (no. CRD42022336841). The Institutional Review Board of Catholic Kwandong University International St. Mary’s Hospital confirmed that ethical approval was not required because this study used previously published papers.

**Search strategy**

A systematic search of MEDLINE/PubMed, Embase, and the Cochrane Library was undertaken to identify candidate articles published between January 2001 and December 2021 reporting OS after different types of treatments in patients with locally advanced HCC accompanied by PVTT and comparing OS according to different modalities. To identify as many appropriate articles as possible, we selected “carcinoma, hepatocellular” or “liver cell carcinomas” or “vascular invasion” or “portal vein invasion” or “portal vein tumor thrombus” as Medical Subject Headings terms. Other keywords such as “sorafenib,” “Nexavar,” “transarterial chemoembolization,” “TACE,” “radiotherapy,” “radiation,” “EBRT,” “radioembolization,” and “TARE” were also used. Detailed search terms used for this analysis are presented in Supplementary Table 1. Titles and corresponding abstracts of articles in search results were examined to select relevant ones. When an article was considered to be potentially relevant to our analysis, 2 researchers (SL and BB) independently reviewed a full copy of the publication based on the inclusion and exclusion criteria stated below. Hazard ratios (HRs) and restricted mean survival time (RMST) were obtained either directly or via the method described below from original articles. They were then combined for the network meta-analysis.

**Inclusion and exclusion criteria**

We selected articles that presented OS after treating patients with HCC accompanied by PVTT following different treatment regimens and provided HR between different treatment groups. If Kaplan-Meier (KM) survival curve was only provided without HR reported, we obtained cumulative HRs using the method described below. Eligible studies were limited to prospective randomized controlled studies, propensity score-matched retrospective cohort studies, and retrospective observational studies using propensity score analysis to reduce bias. If 2 or more studies shared identical cohort data, the one using more accumulated data was selected. Articles published in non-English language were excluded.

**Data extraction**

Two researchers (BB and YP) extracted data of the first author, year of publication, country of origin, study design, the number of patients, demographics of patients, each treatment regimen, and estimated HR and RMST between 2 different treatment groups. The extent of PVTT was reclassified according to the General Rules for the Study of Primary Liver Cancer by the Korean Liver Cancer Study Group as Vp0–Vp4 [8].
Reconstructing Kaplan-Meier data and obtaining cumulative hazard ratios

If obtainable from the original article, HR and 95% confidential interval (CI) between 2 different treatment groups were recorded. If not available, KM survival data were secondarily restored from printed survival curves to calculate HR. The number of patients at risk at time interval points and the total number of events were obtained from the text. Coordinates of time and survival probability were obtained from original survival curves printed on the paper employing the DigitizeIt software (www.digitizeit.de). Restored KM survival data of 2 different treatment groups were combined to calculate HR of corresponding study by applying a unique algorithm proposed in a previous study [9]. RMST differences between treatment groups were also obtained using restored KM survival data. Secondarily computed HRs and RMST differences were used for network meta-analysis with original ones.

Assessing risk of bias in included studies

The quality of each study included in this analysis was formally assessed using the modified Newcastle-Ottawa Scale (NOS) that included selection, comparability, and outcome.

Table: Search results

| Records identified from database searches: | Records removed before screening: |
|------------------------------------------|----------------------------------|
| MEDLINE/PubMed (n = 1,188)               | Duplicate records removed (n = 880) |
| Embase (n = 716)                         |                                  |
| Cochrane (n = 395)                       |                                  |
| Additional records identified through hand searches (n = 9) |                                  |

| Records screened (n = 1,428) | Records excluded after checking titles (n = 1,192) |
|-------------------------------|---------------------------------|
| Reports sought for retrieval (n = 236) | Reports excluded after checking abstracts (n = 171) |

| Records assessed for eligibility (n = 65) | Reports excluded with reasons: |
|------------------------------------------|-------------------------------|
| Inappropriate cohort (n = 38)            | Inappropriate cohort (n = 38) |
| Did not perform propensity matching (n = 10) | Did not perform propensity matching (n = 10) |
| Included patients with extrahepatic metastasis (n = 6) | Included patients with extrahepatic metastasis (n = 6) |

Studies included in network meta-analysis (n = 11)

Fig. 1. Flow chart showing study selection process and search results.

Statistical analyses

All statistical analyses were performed using R software ver. 3.6.3 (R Foundation for Statistical Computing, Vienna, Austria). “Survival” package in R was used for HR calculation. The RMST difference was estimated using the “survRM2” package. Network meta-analyses were conducted employing the “netmeta” package. Endpoints in this network meta-analysis were HRs, mean difference (MD) of survival length compared to systemic therapy with sorafenib alone, and corresponding 95% CIs using random-effects model. Each treatment regimen was then ranked using the P-score provided by the “netmeta” package to assess the probability of the superiority of each treatment regimen. Statistical significance was set at P < 0.05. The I2 statistics provided a measure for the percentage of total variation attributable to heterogeneity between studies. Heterogeneity was considered significant when the I2 value exceeded 50% [10].

RESULTS

Search results

Detailed results from the search strategy are presented in Supplementary Table 1. Of 1,428 non-duplicate studies identified in the literature search, 1,192 were excluded due to
their irrelevant titles. The remaining 236 studies were screened again based on their abstracts and 65 studies were selected for full-text review. Finally, 11 studies were found to be qualified for analysis [7,11-20]. A flow diagram of the literature searches and selection process is shown in Fig. 1. The 11 studies included 1 prospective randomized trial, 9 propensity-matched retrospective cohort studies, and 1 retrospective cohort study implementing propensity score adjustment in a regression model. Seven studies were conducted in East Asian countries (China and Korea) and 4 were conducted in European countries (France, Germany, and Italy). Those 11 studies included for analysis had NOS scores ranging from 5 to 9, indicating a high quality (7 studies with NOS scores of 7-9 and 4 studies with NOS scores of 5-6) (Fig. 2). Because of a multi-arm design in 1 study, 16 pairwise comparisons were available for 12 different treatment regimens: (1) systemic therapy with sorafenib alone, which was used as the reference treatment regimen; (2) best supportive care; (3) SR; (4) SR followed by portal vein chemotherapy (PVC); (5) radiofrequency ablation (RFA) with sorafenib therapy; (6) external beam radiation therapy (EBRT); (7) selective internal radiation therapy (SIRT); (8) TACE; (9) TACE with EBRT; (10) TACE combined with SIRT; (11) TACE combined with SIRT. (Fig. 3). Network of studies for network meta-analysis applying treatments for patients with hepatocellular carcinoma accompanied by portal vein tumor thrombus. PVC, portal vein chemotherapy; EBRT, external beam radiation therapy; TACE, transarterial chemoembolization; BSC, best supportive care; TARE, transarterial radioembolization; SIRT, selective internal radiation therapy; RFA, radiofrequency ablation.

| Study            | Selection | Comparability | Outcome | Quality score |
|------------------|-----------|---------------|---------|---------------|
| Edeline [12] (2016) | ★ - ★ - ★ | ★ - ★ - ★ | 5       |
| Giorgio [14] (2016) | ★ ★ ★ ★ | ★ ★ - ★ | 7       |
| Cho [11] (2016)   | ★ ★ ★ | ★ - ★ | 6       |
| Shen [17] (2018)  | ★ ★ ★ | ★ - - | 6       |
| Gao [13] (2019)   | ★ - ★ | ★ - ★ | 7       |
| Xiang [19] (2019) | ★ ★ ★ | ★ ★ - | 8       |
| Yuan [20] (2019)  | - ★ ★ | ★ - - | 6       |
| Mei [7] (2020)    | - ★ ★ | ★ ★ - | 8       |
| Su [18] (2020)    | - ★ ★ | ★ ★ - | 8       |
| Martelletti [15] (2021) | ★ ★ ★ | ★ ★ | 7       |
| Mähringer-Kunz [16] (2021) | ★ ★ ★ | ★ ★ | 9       |

(Fig. 2). Modified Newcastle-Ottawa Scale assessment of selected studies.

(Fig. 3). Network of studies for network meta-analysis applying treatments for patients with hepatocellular carcinoma accompanied by portal vein tumor thrombus. PVC, portal vein chemotherapy; EBRT, external beam radiation therapy; TACE, transarterial chemoembolization; BSC, best supportive care; TARE, transarterial radioembolization; SIRT, selective internal radiation therapy; RFA, radiofrequency ablation.
Table 1. Characteristics of included studies and patient demographics

| Study            | Year | Study design (country) | Study period | Treatment modality | No. of patients, M/F | Age (yr) | Type of PVTT | Cirrhosis, yes/no | CP, A/B | Max. size of tumors (mm) | Tumor marker (α-FP) | Origin, viral/ others |
|------------------|------|------------------------|--------------|--------------------|----------------------|----------|--------------|-------------------|---------|--------------------------|----------------------|------------------------|
| Edeline et al.   | 2016 | RC, PSM (France)       | 2005–2012    | Sorafenib SIRT     | 23/1                 | 64.6 ± 7.8          | (Vp1–3/Vp4) 16/8 | 21/3 | 21/3 | 67.1 ± 29.8              | (>400/≤400) 7/17 | 8/16 |
| Giorgio et al.   | 2016 | RCT (Italy)            | 2011–2014    | Sorafenib RFA + sorafenib | 36/14                | 72 (70–76)          | 50 (Vp4) | 500 | 500 | 75.0 ± 33.8              | 9/15 | 7/17 |
|                  |      |                        |              |                    | 37/12               | 71 (69–75)          | 49 (Vp4) | 49/0 | 49/0 | 65 (mean 43)            | NA | 92/7, total |
| Cho et al.       | 2016 | RC, PSM (Korea)        | 2008–2013    | TARE Sorafenib     | 26/6                 | 63.7 ± 11.1         | (Vp2/3/4) 12/20/0 | NA | 28/4 | NA                       | (>200/≤200) 20/12 | 28/4 |
| Shen et al.      | 2018 | RC, PSM (China)        | 2009–2017    | TACE + sorafenib   | 24/2                 | 63.7 ± 11.1         | (Vp2/3/4) 12/20/0 | NA | 23/3 | 75.0 ± 33.8              | 9/15 | 7/17 |
| Gao et al.       | 2019 | RC, PSM (China)        | 2009–2015    | Resection + PVC    | 58/9                 | 63.7 ± 11.1         | (Vp2/3/4) 12/20/0 | NA | 23/3 | 75.0 ± 33.8              | 9/15 | 7/17 |
| Xiang et al.     | 2019 | RC, PSM (China)        | 2003–2013    | TACE BSC           | 320/30               | 63.7 ± 11.1         | (Vp2/3/4) 12/20/0 | NA | 23/3 | 75.0 ± 33.8              | 9/15 | 7/17 |
| Yuan et al.      | 2019 | RC, PSM (China)        | 2008–2014    | TACE TACE + sorafenib | 117/21              | 63.7 ± 11.1         | (Vp2/3/4) 12/20/0 | NA | 23/3 | 75.0 ± 33.8              | 9/15 | 7/17 |
| Mei et al.       | 2020 | RC, PSM (China)        | 2005–2017    | Resection Sorafenib | 59/10               | 63.7 ± 11.1         | (Vp2/3/4) 12/20/0 | NA | 23/3 | 75.0 ± 33.8              | 9/15 | 7/17 |
| Su et al.        | 2020 | RC, PSM (China)        | 2000–2016    | EBRT EBRT + TACE   | 37/4                 | 63.7 ± 11.1         | (Vp2/3/4) 12/20/0 | NA | 23/3 | 75.0 ± 33.8              | 9/15 | 7/17 |
| Martianetti et al. | 2021| RC, PSM (Italy)       | 2012–2018   | Resection sorafenib | 23/6                 | 63.7 ± 11.1         | (Vp2/3/4) 12/20/0 | NA | 23/3 | 75.0 ± 33.8              | 9/15 | 7/17 |
| Mähringer-Kunz et al. | 2021 | RC, PS (Germany)      | 2005–2016    | Resection TACE + SIRT Sorafenib BSC | 231/47, total | 65.6 (27–87), total | (Vp2/3/4) 12/20/0 | 232/46 | (A/B/C) | 65.6 (27–87), total | (Vp2/3/4) 12/20/0 | 232/46 |

M, male; F, female; PVTT, portal vein tumor thrombus; CP, Child-Pugh class; RC, retrospective cohort; PSM, propensity score matching; SIRT, selective internal radiation therapy; RCT, randomized control trial; RFA, radiofrequency ablation; NA, not available; TARE, transarterial radioembolization; TACE, transarterial chemoembolization; EBRT, external beam radiation therapy; PVC, portal vein chemotherapy; MELD, model for end stage liver disease; PS, propensity score adjustment; BSC, best supportive care.
with sorafenib therapy, and (12) transarterial radioembolization (TARE). The network diagram for OS is presented in Fig. 3.

Characteristics and demographics of selected studies

Characteristics of patients enrolled in the 11 selected studies are provided in Table 1. A total of 1,623 patients were included for data analysis. Most treatment groups were composed predominantly of patients with Child-Pugh class A cirrhosis. All studies included more male patients than female patients. Viral hepatitis was the predominant etiology of HCC in most studies. Serum α-FP levels were markedly elevated in most patients with HCC accompanied by PVTT. On average, 47.7% (range, 23.8%–100%) of PVTT status was Vp4.

Network meta-analysis results

Results of random-effects network meta-analysis are summarized in Fig. 4. Indirect estimates of HRs comparing sorafenib therapy alone vs. other treatment regimens are presented in Fig. 4A. For OS, 4 treatment regimens had relatively higher efficiency than sorafenib therapy alone. Patients treated with SR (HR, 0.44; 95% CI, 0.33–0.58), SR followed by PVC (HR, 0.26; 95% CI, 0.16–0.42), RFA with sorafenib therapy (HR, 0.35; 95% CI, 0.19–0.64), and TACE combined with SIRT (HR, 0.72; 95% CI, 0.56–0.92) had significantly lower HR for OS than those with sorafenib therapy alone. SR followed by PVC was ranked
the best treatment regimen for OS (P-score, 93.9%), followed by RFA with sorafenib therapy (P-score, 86.0%), SR (P-score, 77.1%), and TACE combined with SIRT (P-score, 55.9%). There was neither significant heterogeneity ($I^2 = 0$) nor inconsistency ($Q = 0.91, P = 0.821$) within treatment regimens compared.

Further analyses were performed to estimate mean survival time difference according to each treatment regimen. It was conducted using RMST based on time-to-event data reconstructed from the KM curves in each original article. Patients treated with SR (MD, 11.57 months; 95% CI, 5.85–17.29 months), SR followed by PVC (MD, 17.48 months; 95% CI, 59.1–29.05 months), and TACE combined with EBRT (MD, 20.71 months; 95% CI, 2.88–38.54 months) had significantly longer survival than those treated with sorafenib therapy alone (Fig. 5). Significant heterogeneity ($I^2 = 86.5%$) and inconsistency ($Q = 35.26, P < 0.001$) existed among original studies.

**DISCUSSION**

Although the standard practical guidelines such as the BCLC and American Association for the Study of Liver Diseases recommend systemic target therapy to treat HCC accompanied by PVTT [21,22], recent studies have stated that patients treated with aggressive locoregional therapeutic modalities such as TARE, TACE/SIRT, and SR have better prognosis than those treated with sorafenib therapy alone [16,23]. These guidelines have a limitation in that they do not distinguish between HCC with gross vascular invasion and those with extrahepatic metastasis, considering them as the same class. However, it would be reasonable to conduct a study for HCC accompanied by PVTT excluding extrahepatic metastasis because they have a chance of being cured with aggressive locoregional treatment regimens. Our work indirectly but comprehensively compared survival outcomes of various treatment regimens using network meta-analysis, in which locoregional therapeutic modalities demonstrated better outcomes than systematic therapy with sorafenib alone. This statistical analysis method could suggest which treatment regimen is most effective for patients with HCC accompanied by PVTT without extrahepatic metastasis. According to our study, SR followed by PVC was ranked the best treatment regimen for those patients. To the best of our knowledge, the work demonstrated here is the first network meta-analysis of comparative efficiency of various treatment regimens for HCC accompanied by PVTT without extrahepatic metastasis.

SR has not been considered an absolute contraindication for patients with HCC accompanied by PVTT [18], but a possible treatment option for selected ones. It has brought great improvement in survival outcomes for patients with HCC accompanied by PVTT due to advanced surgical techniques and establishment of methods for patient selection [24]. One study has demonstrated that the median OS is 20.7 months in the SR group and 11.6 months in the sorafenib group [7]. However, more than 80% of patients appeared to have unresectable HCC at the time of diagnosis. Only a limited group of patients can be candidates for SR. In addition, SR is associated with risk of hospital mortality and postoperative complications. Patients should be carefully selected for SR according to their performance status and remnant liver function reserve. If PVTT is confined to segmental or sectional branches of the portal vein, anatomical resection can secure tumor-free margins. When the PVTT extends to the major branch or the main portal vein, *en-bloc* resection of portal vein or a concomitant thrombectomy could be performed [25].

Despite surgical management, owing to its poor prognosis and high recurrence rate, the need for adjuvant therapy for PVTT has been advocated. Various adjuvant treatments have been investigated and some of them have been reported to be able to prolong OS. Peng et al. [26] have assessed postoperative TACE with a randomized comparative trial. Sun et al. [27] have carried out a randomized controlled trial for postoperative adjuvant intensity modulated radiation therapy. Both studies showed better survival outcome of the treatment group than that of the control group [26,27]. However, studies comparing superiority of adjuvant treatment have not been reported yet. A multicenter randomized control is needed. In our study, PVC was performed as adjuvant therapy. It was ranked as the best treatment for HCC accompanied by PVTT. However, PVC is technically not feasible under some circumstances. Thus, its practical application is limited. More investigation is needed to validate the most proper postoperative management.

TACE has been widely used for unresectable HCC. Its technical development has helped more patients achieve better survival outcome. TACE is one of the locoregional treatments that carry anticancer agents directly to cancer through tumor feeding artery. Previously, TACE was perceived as a contraindication to patients with HCC accompanied by PVTT, especially when thrombosis was present in the main portal vein [4,5]. It is attributed to theory that TACE has an embolization effect, which can worsen the liver function by reducing blood supply. However, some studies have stated that if collateral circulation is intact, TACE is applicable regardless of PVTT type without severe complications [28]. In addition, liver necrosis rarely occurs after TACE. There are limited treatment options for HCC accompanied by PVTT. Considering the safety of TACE, it is commonly chosen for patients with HCC accompanied by PVTT in practice. Based on recent studies, TACE is obviously superior to the best supportive care [19]. However, compared to sorafenib, its superiority is not clearly identified. Instead, combinations of various treatments can lead to a better prognosis than TACE alone. Especially, combination treatment of TACE and sorafenib and combination treatment of...
TACE and EBRT offered better survival outcomes than sorafenib alone in our study.

Another treatment option for HCC accompanied by PVTT is EBRT. Most concerns about radiation therapy in HCC are assertions that HCC is a radio-resistant tumor and that serious complications can occur due to radiation-induced liver disease. However, multiple studies have shown that EBRT is a safe and effective treatment option for unresectable HCC. With the improvement of radiation delivery techniques that enable us to localize tumor, radiation therapy is playing an important role in multidisciplinary treatment for HCC accompanied by PVTT. One retrospective study using propensity score matching has argued that EBRT should be the first-line therapy, especially for HCC accompanied by PVTT, rather than sorafenib since EBRT can lead to longer survival time [29]. However, serious unsolved problems such as radiation-induced lung disease and bowel toxicity limit the application of EBRT [30]. Further studies on effectiveness and safety of EBRT are needed.

This study has several limitations. First, only 1 prospective randomized trial was included. Other included studies were all retrospective ones. However, we selected retrospective studies with propensity score matching to reduce bias. Second, newly introduced chemotherapeutic agents were not included in this study. Recently, according to the BCLC guideline published in 2022, atezolizumab combined with bevacizumab or durvalumab combined with tremelimumab was newly recommended for 1st line therapy in patients with advanced stage of HCC. However, published studies comparing sorafenib and other chemotherapeutic agents included patients with advanced stage HCC including extrahepatic metastasis. These articles were excluded because our study targeted patients with HCC accompanied by PVTT without extrahepatic metastasis. Third, the results of this study cannot be uniformly applied to all patients with HCC accompanied by PVTT. Most of the patients included in this study had compensated liver cirrhosis for whom aggressive locoregional treatments were possible. Lastly, since a wide variety of treatment regimens are applied to HCC accompanied by PVTT, network meta-analysis with all regimens is virtually impossible. Therefore, further study comparing the different treatment regimens classified based on the mainstay treatment such as SR, TACE, and stereotactic body radiation therapy is necessary.

In conclusion, results of our study support that aggressive locoregional treatment with or without combination of systemic therapy can bring better survival outcomes for patients with HCC accompanied by PVTT rather than systemic treatment with sorafenib alone. Thus, we propose that aggressive locoregional treatments such as SR or TACE combined with EBRT should be considered for patients with HCC accompanied by PVTT.

SUPPLEMENTARY MATERIALS

Supplementary Table 1 can be found via https://doi.org/10.4174/astr.2022.103.5.280.

ACKNOWLEDGEMENTS

Fund/Grant Support
None.

Conflict of Interest
The first author was the second place winner of Young Investigator Award in the 2022 Annual Spring Congress of the Korean Surgical Society, Gwangju on May 28, 2022. No other potential conflicts of interest relevant to this article was reported.

ORCID iD
Seungji Lee: https://orcid.org/0000-0001-7990-915X
Sung Kyu Song: https://orcid.org/0000-0003-0170-0802
Byungje Bae: https://orcid.org/0000-0001-8192-1693
Yongkeun Park: https://orcid.org/0000-0001-9481-6542

Author Contribution
Conceptualization, Project Administration: SL, YP
Formal Analysis: SL, BB, YP
Investigation: SL, SKS, BB
Methodology: YP
Writing – Original Draft: SL, SKS, YP
Writing – Review & Editing: All authors

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
2. Hong SK, Lee KW, Lee S, Hong SY, Suh S, Han ES, et al. Impact of tumor size on hepatectomy outcomes in hepatocellular carcinoma: a nationwide propensity score matching analysis. Ann Surg Treat Res 2022;102:193-204.
3. Kim JM, Rhu J, Ha SY, Choi GS, Kwon CH, Kim G, et al. Realization of improved outcomes following liver resection in...
hepatocellular carcinoma patients aged 75 years and older. Ann Surg Treat Res 2021:101:257-65.
4. Costentin CE, Ferrone CR, Arellano RS, Ganguli S, Hong TS, Zhu AX. Hepatocellular carcinoma with macrovascular invasion: defining the optimal treatment strategy. Liver Cancer 2017;6:360-74.
5. Cerrito L, Annicchiarico BE, Iezzi R, Gasbarrini A, Pompili M, Ponziani FR. Treatment of hepatocellular carcinoma in patients with portal vein tumour thrombosis: beyond the known frontiers. World J Gastroenterol 2019;25:4360-82.
6. Qadan M, Kothary N, Sangro B, Palta M. The treatment of hepatocellular carcinoma with portal vein tumour thrombosis. Am Soc Clin Oncol Educ Book 2020:40.1-8.
7. Mei J, Li SH, Wang QX, Lu LH, Ling YH, Zou JW, et al. Resection vs. sorafenib for hepatocellular carcinoma with macroscopic vascular invasion: a real world, propensity score matched analytic study. Front Oncol 2020:10:573.
8. Jang JY, Lee JS, Kim HJ, Shim JJ, Kim JH, Kim BH, et al. The general rules for the study of primary liver cancer. J Liver Cancer 2017;17:19-44.
9. Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol 2012:12:9.
10. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
11. Cho YY, Lee M, Kim HC, Chung JW, Kim YH, Gwak GY, et al. Radioembolization is a safe and effective treatment for hepatocellular carcinoma with portal vein thrombosis: a propensity score analysis. PLoS One 2016:11:e0154986.
12. Édeline J, Cruzet L, Campillo-Gimenez B, Rolland Y, Fracht M, Guillygomarch A, et al. Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis. Eur J Nucl Med Mol Imaging 2016:43:635-43.
13. Gao Y, Wang PX, Cheng JW, Sun YF, Hu B, Guo W, et al. Chemotherapeutic perfusion of portal vein after tumor thrombectomy and hepatectomy benefits patients with advanced hepatocellular carcinoma: a propensity score matched survival analysis. Cancer Med 2019:8:6933-44.
14. Giorgio A, Merola MG, Montesarchio L, Merola F, Santoro B, Coppola C, et al. Sorafenib combined with radio-frequency ablation compared with sorafenib alone in treatment of hepatocellular carcinoma invading portal vein: a Western randomized controlled trial. Anticancer Res 2016:36:6179-83.
15. Martelletti C, Ricotti A, Gesualdo M, Carucci P, Gaia S, Rolle E, et al. Radioembolization vs sorafenib in locally advanced hepatocellular carcinoma with portal vein tumour thrombosis: a propensity score and Bayesian analysis. J Dig Dis 2021:22:496-502.
16. Mähringer-Kunz A, Steinle V, Kloeckner R, Schotten S, Hahn F, Schmidtmann I, et al. The impact of portal vein tumour thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: a cohort study. PLoS One 2021:16:e0249426.
17. Shen L, Xi M, Zhao L, Zhang X, Wang X, Huang Z, et al. Combination therapy after TACE for hepatocellular carcinoma with macroscopic vascular invasion: stereotactic body radiotherapy versus sorafenib. Cancers (Basel) 2018:10:516.
18. Su TS, Li LQ, Meng WW, Wang YD, Zhao C, Ma YL, et al. Long-term survival analysis of transarterial chemoembolization plus radiotherapy vs. radiotherapy for hepatocellular carcinoma with macroscopic vascular invasion. Front Oncol 2020:10:1205.
19. Xiang X, Lau WY, Wu ZY, Zhao C, Ma YL, Xiang BD, et al. Transarterial chemoembolization versus best supportive care for patients with hepatocellular carcinoma with portal vein tumour thrombus: a multicenter study. Eur J Surg Oncol 2019:45:1460-7.
20. Yuan J, Yin X, Tang B, Ma H, Zhang L, Li L, et al. Transarterial chemoembolization (TACE) combined with sorafenib in treatment of HBV background hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study. Biomed Res Int 2019:2019:2148189.
21. Reig M, Forner A, Rimola A, Fuster-Fabrega J, Burrel M, García-Criado Á, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol 2022:76:681-93.
22. Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassiss MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2018:68:723-50.
23. Vilgrain V, Pereira H, Assenat E, Guio B, Ilonca AD, Pageaux GP, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol 2017;18:1624-36.
24. Ye JZ, Wang YY, Bai T, Chen J, Xiang BD, Wu FX, et al. Surgical resection for hepatocellular carcinoma with portal vein tumor thrombus in the Asia-Pacific region beyond the Barcelona Clinic Liver Cancer treatment algorithms: a review and update. Oncotarget 2017;8:93258-78.
25. Zhang YF, Le Y, Wei W, Zou RH, Wang JH, OuYang HY, et al. Optimal surgical strategy for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score analysis. Oncotarget 2016:7:38845-56.
26. Peng BG, He Q, Li JP, Zhou F. Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Surg 2009:198:313-8.
27. Sun J, Yang L, Shi J, Liu C, Zhang X, Chai Z, et al. Postoperative adjuvant IMRT for patients with HCC and portal vein tumor thrombus: an open-label randomized controlled trial. Radiother Oncol 2019:140:
28. Zhang X, Wang K, Wang M, Yang G, Ye X, Wu M, et al. Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis. Oncotarget 2017;8:29416-27.

29. Nakazawa T, Hidaka H, Shibuya A, Okuwaki Y, Tanaka Y, Takada J, et al. Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis. BMC Gastroenterol 2014;14:84.

30. Yu JI, Park HC. Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol 2016;22:6851-63.